课题组简介
1. 鉴定和评估新冠突变株免疫逃逸、受体亲和力等生物学特性，第一时间内提供相关科研数据给政府以及世界卫生组织（WHO），为疫情防控提供科学指导。
2.评估新冠mRNA疫苗诱导保护性抗体的能力，率先报道奥密克戎BA.5双价mRNA疫苗存在免疫印迹问题限制其疫苗的免疫效果，帮助指导新冠mRNA疫苗的更新换代。
3.分离鉴定多种表位新冠广谱中和性抗体，丰富了对新冠病毒免疫原性认识。
4.拥有7项新冠抗体以及新冠检测试剂盒的国际专利，其中新冠检测试剂盒获得加拿大卫生部授权上市。
5.研究多种形式膜结合抗体，用于高效阻断游离和细胞介导艾滋病病毒感染。
1.专业要求：生物信息学及相关专业，获得博士学位，符合博士后进站条件；
2.能熟练使用 C/C++/R 等高性能语言及软件工具进行生物信息学数据分析，能利用各类计算和统计学技术开发新的数据分析方法，撰写分析报告和 SCI 研究论文；
3.能独立开展并指导相关研究生完成生物信息方向的研究工作；
4.具有浓厚的前沿科学探索兴趣，有较强的独立科研能力，以第一作者身份在国际权威期刊发表过原创性研究论文；
1.本科或硕士以上学历，具有病毒学、免疫学、细胞生物学、生物化学、分子生物学及相关方向的研究背景和研究经历者优先；
2.熟悉分子克隆、细胞生物学、蛋白纯化等基本实验技能；
3.具备良好英文读写能力；
1.个人简历，包括学习工作经历、主要研究方向、代表性论文论著清单、获奖情况。
2.学历学位证书、身份证扫描件。
3. Cover letter: 简要介绍既往工作、研究兴趣和职业规划。
4.其他能证明应聘者能力的相关资格证书和证明材料。
根据武汉大学相关规定以及个人工作能力，提供具有竞争力的薪酬待遇以及科研条件，享受五险一金等相关福利，具体薪资面谈。
该招聘长期有效，招满为止。
1.Liu L, Casner RA, Guo Y, Wang Q, Iketani S, Chan JFW, Yu J, Dadonaite B, Nair MS, Mohri H, Reddem ER, Yuan S, Poon VK, Chan CC, Yuen KY, Sheng Z, Huang Y, Bloom JD, Shapiro L, Ho DD. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. Immunity. 2023 Oct 10;56(10):2442-2455.e8.
2.Liu L, Iketani S, Guo Y, Reddem ER, Casner RG, Nair MS, Yu J, Chan JF, Wang M, Cerutti G, Li Z, Morano NC, Castagna CD, Corredor L, Chu H, Yuan S, Poon VK, Chan CC, Chen Z, Luo Y, Cunningham M, Chavez A, Yin MT, Perlin DS, Tsuji M, Yuen KY, Kwong PD, Sheng Z, Huang Y, Shapiro L & Ho DD. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Science translational medicine. 2022; 14(646):eabn6859.
3.Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair MS, Yu J, Chik KK, Yuen TT, Yoon C, To KK, Chen H, Yin MT, Sobieszczyk ME, Huang Y, Wang HH, Sheng Z, Yuen KY & Ho DD. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 2022; 602(7898):676-81.
4.Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L and Ho DD. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020; 584(7821): 450-456.
1.Wang Q, Guo Y, Schwanz LT, Mellis IA, Sun Y, Qu Y, Urtecho G, Valdez R, Stoneman E, Gordon A, Wang HH, Ho DD#, Liu L#. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1. Emerg Microbes Infect. 2024 Dec;13(1):2359004. (# corresponding author).
2.Wang Q, Mellis IA, Ho J, Bowen A, Kowalski-Dobson T, Valdez R, Katsamba PS, Wu M, Lee C, Shapiro L, Gordon A#, Guo Y#, Ho DD#, Liu L#. Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages. Emerg Microbes Infect. 2024 Dec;13(1):2402880. (# corresponding author).
3.Wang Q, Mellis IA, Guo Y, Gherasim C, Valdez R, Gordon A#, Ho DD#, Liu L#. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster. Cell Rep Med. 2024 Sep 17;5(9):101701. (# corresponding author).
4.Wang Q, Guo Y, Liu L, Schwanz LT, Li Z, Nair MS, Ho J, Zhang RM, Iketani S, Yu J, Huang Y, Qu Y, Valdez R, Lauring AS, Huang Y, Gordon A, Wang HH, Liu L#, Ho DD#. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature. 2023 Dec;624(7992):639-644. (# corresponding author).
5.Wang Q, Bowen A, Ho J, Zhang RM, Valdez R, Stoneman E, Gordon A, Liu L#, Ho DD#. SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster. Lancet. 2023 Nov 18;402(10415):1827-1828. (# corresponding author)
6.Wang Q, Guo Y, Zhang RM, Ho J, Mohri H, Valdez R, Manthei DM, Gordon A, Liu L#, Ho DD#. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. Lancet Infect Dis. 2023 Oct;23(10):e397-e398. (# corresponding author)
7.Wang Q, Yeh AY, Guo Y, Mohri H, Yu J, Ho DD, Liu L#. Impaired potency of neutralizing antibodies against cell-cell fusion mediated by SARS-CoV-2. Emerg Microbes Infect. 2023 Dec;12(1):2210237. (# corresponding author)
8.Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C, Gordon A, Liu L#, Ho DD#. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe. 2024 Mar 13;32(3):315-321.e3. (# corresponding author)
9.Wang Q, Bowen A, Tam AR, Valdez R, Stoneman E, Mellis IA, Gordon A, Liu L#, Ho DD#. SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster. Lancet Infect Dis. 2023 May;23(5):527-528. (# corresponding author)
10.Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L#, Ho DD#. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023 Jan 19;186(2):279-286.e8. (# corresponding author)
11.Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L#, Ho DD#. Antibody Response to Omicron BA.4-BA.5 Bivalent Booster. New England Journal of Medicine 2023 Feb 9;388(6):567-569. (# corresponding author)
12.Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Liu M, Wang M, Yu J, Sheng Z, Huang Y, Liu L#, Ho DD#. Resistance of SARS-CoV-2 Omicron Subvariant BA.4.6 to Antibody Neutralization. Lancet Infect Dis 2022 Oct 31:S1473-3099(22)00694-6. (# corresponding author)
13.Wang Q, Iketani S, Li Z, Guo Y, Yeh AY, Liu M, Yu J, Sheng Z, Huang Y, Liu L#, Ho DD#. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. Cell Host & Microbe 2022 Sep 6:S1931-3128(22)00419-X. (# corresponding author)
